Empowering dialysis users and caregivers
Search for dialysis centres here
Log in to explore the world's most comprehensive database of dialysis centres for free!
Professional dialysis recruitment| Brokerage Firm Focus: Rockwell Medical, Inc. (NASDAQ:RMTI) - The Markets Daily |
 |
 |
|
On a consensus basis, Street analysts are expecting Rockwell Medical, Inc. (NASDAQ:RMTI) to report earnings per share of $-0.1 for the quarter ending 2015-03-31. The company is next slated to report quarterly earnings on or around 2015-05-11. Rockwell Medical, Inc. (NASDAQ:RMTI) last reported quarterly EPS of $-0.14 for the quarter ended 2014-12-31 on 2015–0-2-26. This number was $-0.08 away from what analysts were expecting, resulting in a surprise factor of -133.33%. There are 5 covering research analysts that have issued an anticipated price level where they predict the stock will reach within the next year. The consensus target for these analysts sits at $16 for Rockwell Medical, Inc.. The highest analyst target sees the stock at $26 within the year. The lowest analyst target sees the stock at $4 over the same time period. Wall Street analysts have a mean estimate for long-term growth of $25 on the stock. When looking at the three months ago number, they had a long-term growth mean estimate of $25 on the company. Placing analyst ratings on a recommendation scale, Rockwell Medical, Inc. has a mean rating of 1.8. Using this scale, a one would represent a Strong Buy recommendation and a five would represent a Strong Sell recommendation. There are 5 broker recommendations that this rating is based on. Profile Rockwell Medical, Inc., formerly Rockwell Medical Technologies, Inc., manufactures hemodialysis concentrate solutions and dialysis kits, and it sells, distributes and delivers these and other ancillary hemodialysis products primarily to hemodialysis providers in the United States, as well as internationally primarily in Asia, Latin America and Europe. Hemodialysis duplicates kidney function in patients with failing kidneys also known as End Stage Renal Disease (ESRD). ESRD is an advanced-stage of chronic kidney disease (CKD) characterized by the irreversible loss of kidney function. Its dialysis solutions (also known as dialysate) are used to maintain life, removing toxins and replacing nutrients in the dialysis patient’s bloodstream. As of December 31, 2011, it was licensed and was developing renal drug therapies. During the year ended December 31, 2011, it acquired an abbreviated new drug application (ANDA) for a generic version of an intravenous Vitamin-D analogue, calcitriol. |
